Theorem Clinical Research

R&D Trends

Alexion, Cincinnati Children’s launch rare disease innovation fund

Wednesday, October 15, 2014 06:30 PM

Alexion Pharmaceuticals, a Cambridge, Mass.-based developer of breakthrough therapies for patients with severe and life-threatening rare diseases, and Cincinnati Children’s Hospital Medical Center have established the Alexion Rare Disease Innovation Fund for the advancement of research in rare disease.

More... »


NIH invests $32 million to increase utility of biomedical research data

Wednesday, October 15, 2014 01:22 PM

The NIH has invested to develop new strategies to analyze and leverage increasingly complex biomedical data sets, often referred to as Big Data. These NIH multi-institute awards constitute an initial investment of nearly $32 million by NIH’s Big Data to Knowledge (BD2K) initiative, which is projected to have a total investment of nearly $656 million through 2020, pending available funds.

More... »


Accenture launches Cloud for R&D, forms Cloud Coalition

Wednesday, October 15, 2014 01:19 PM

Accenture, an Ireland-based global management consulting, technology services and outsourcing company, has launched Accenture Life Sciences Cloud for R&D, which speeds clinical development, helps improve patient outcomes and creates greater R&D efficiency through a new single analytics platform that brings together multiple internal and external data sources across clinical, safety, regulatory and operational functions.

More... »

Children's National Urea Cycle Disorders Consortium awarded $6M by NIH

Monday, October 13, 2014 09:05 AM

Children's National Health System's Urea Cycle Disorders Consortium, based in Wash. D.C., was awarded $6.25 million over the next five years from the NIH to perform clinical research and develop new treatments for patients with urea cycle disorders (UCD), which are rare but devastating genetic conditions.

More... »

Oxford BioMedica, Novartis colaborate

Monday, October 13, 2014 08:57 AM

Oxford BioMedica, a U.K. gene and cell therapy company, has signed contracts with Novartis which build on a collaboration between the companies announced May 2013.

More... »

Report: Pain medicine market forecast to reach $38 billion by 2028

Friday, October 10, 2014 11:57 AM

The overall pain market will maintain $38 billion in sales in 2028 across the major pharmaceutical markets (U.S., France, Germany, Italy, Spain, the U.K. and Japan), according to Burlington, Mass.-based Decision Resources Group.

More... »

Report: U.K. leads Europe in capital raised and pipeline of products

Thursday, October 9, 2014 11:00 AM

The U.K. biotech ecosystem continues to flourish based on strong fundamentals, according to a new State of the Nation report by Ernst & Young and the BioIndustry Association (BIA), a trade association for innovative enterprises involved in U.K. bioscience.

More... »

Bristol-Myers Squibb, Novartis collaborate on NSCLC

Thursday, October 9, 2014 10:00 AM

Bristol-Myers Squibb has established a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of combining Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) with three molecularly targeted oncology therapies (Zykadia (ceritinib), INC280 and EGF816) from Novartis. Novartis will conduct two phase I/II studies focused on non-small cell lung cancer (NSCLC).

More... »

Bristol-Myers Squibb, MD Anderson Cancer Center collaborate

Thursday, October 9, 2014 09:30 AM

Bristol-Myers Squibb and the University of Texas MD Anderson Cancer Center have formed a novel clinical research collaboration to evaluate multiple immunotherapies, including Opdivo (nivolumab), Yervoy (ipilimumab) and three early-stage clinical immuno-oncology assets from Bristol-Myers Squibb, as potential treatment options for acute and chronic leukemia as well as other hematologic malignancies.

More... »

Second Genome, Mayo Clinic collaborate to develop microbiome therapeutics

Thursday, October 9, 2014 09:00 AM

Second Genome, a South San Francisco, Calif.-based developer of novel medicines through innovative microbiome science, has entered into an extensive partnership with the Minnesota-based Mayo Clinic Center for Individualized Medicine to support the development of therapeutic products for multiple disease indications, starting with inflammatory bowel disease, metabolic disorders and colorectal cancer.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs